Ovid Therapeutics Tops Q4 Estimates with $0.06 EPS, Secures $81M Funding
Ovid Therapeutics reported Q4 2025 EPS of $0.06, topping estimates by $0.16 per share, and posted revenue of $718,000 versus forecasts under $80,000, marking over 158% earnings surprise. A recent $81 million private placement secures funding into late 2028 for OV329 and OV4071 clinical programs.
1. Q4 Earnings Beat
Ovid Therapeutics delivered Q4 2025 EPS of $0.06, outperforming a projected $0.10 loss and representing a 158% surprise. Revenue reached $718,000, far above consensus forecasts below $80,000, reflecting increased collaboration and licensing activities in its neurological disorder programs.
2. Private Placement Strengthens Cash Position
In October 2025 Ovid completed an $81 million private placement, bolstering its cash, equivalents and marketable securities. This financing is expected to fund operations and key clinical studies through the second half of 2028, extending the company’s runway.
3. Pipeline Outlook for OV329 and OV4071
Ovid is advancing OV329, a next-generation GABA-aminotransferase inhibitor, and OV4071, an oral KCC2 activator, both targeting rare neurological disorders. The company plans to initiate pivotal trials for OV329 later in 2026 while progressing OV4071 into Phase 1 studies, positioning its pipeline for upcoming data readouts.